Following the encouragement of the buyout of Scheing-Plough by Merck, the drug giant Roche once again stirred up the discussion of acquiring Genentch. The two companies had earlier conversations which fell through due to a solid consensus on the pricing issue. Roche has now offered a price tag of $93 per share. If they still bump up the value by two dollar per share, the deal would be valued at $46.7 billion. Genentech authorities are looking for a value of more than $100 per share.
We will wait and watch how the deals goes and if at all it goes or not. The likelihood of it making through is rather high is what my feeling is.
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment